Compare Fresenius Kabi Onco. with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PIRAMAL ENTERPRISES - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PIRAMAL ENTERPRISES FRESENIUS KABI ONCO./
PIRAMAL ENTERPRISES
 
P/E (TTM) x 22.1 18.4 120.0% View Chart
P/BV x 3.1 1.2 265.8% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 FRESENIUS KABI ONCO.   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PIRAMAL ENTERPRISES
Mar-19
FRESENIUS KABI ONCO./
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1763,303 5.3%   
Low Rs791,797 4.4%   
Sales per share (Unadj.) Rs37.7716.5 5.3%  
Earnings per share (Unadj.) Rs5.179.7 6.4%  
Cash flow per share (Unadj.) Rs6.7107.9 6.2%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs42.51,477.5 2.9%  
Shares outstanding (eoy) m158.23184.45 85.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.43.6 94.9%   
Avg P/E ratio x25.032.0 78.1%  
P/CF ratio (eoy) x18.923.6 80.1%  
Price / Book Value ratio x3.01.7 173.3%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m20,135470,292 4.3%   
No. of employees `0001.27.8 14.7%   
Total wages/salary Rs m70322,504 3.1%   
Avg. sales/employee Rs Th5,176.216,899.4 30.6%   
Avg. wages/employee Rs Th610.42,877.7 21.2%   
Avg. net profit/employee Rs Th699.61,879.9 37.2%   
INCOME DATA
Net Sales Rs m5,963132,153 4.5%  
Other income Rs m183,128 0.6%   
Total revenues Rs m5,981135,281 4.4%   
Gross profit Rs m1,43066,290 2.2%  
Depreciation Rs m2585,202 5.0%   
Interest Rs m-2644,097 -0.1%   
Profit before tax Rs m1,21620,119 6.0%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3428,611 4.0%   
Profit after tax Rs m80614,701 5.5%  
Gross profit margin %24.050.2 47.8%  
Effective tax rate %28.142.8 65.7%   
Net profit margin %13.511.1 121.5%  
BALANCE SHEET DATA
Current assets Rs m5,102122,742 4.2%   
Current liabilities Rs m2,385310,810 0.8%   
Net working cap to sales %45.6-142.3 -32.0%  
Current ratio x2.10.4 541.6%  
Inventory Days Days15023 650.4%  
Debtors Days Days11339 291.7%  
Net fixed assets Rs m5,148116,904 4.4%   
Share capital Rs m158369 42.9%   
"Free" reserves Rs m6,556272,161 2.4%   
Net worth Rs m6,732272,530 2.5%   
Long term debt Rs m952270,196 0.4%   
Total assets Rs m10,388856,261 1.2%  
Interest coverage x-45.81.5 -3,143.5%   
Debt to equity ratio x0.11.0 14.3%  
Sales to assets ratio x0.60.2 371.9%   
Return on assets %7.56.9 109.3%  
Return on equity %12.05.4 221.9%  
Return on capital %14.612.4 117.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29815,200 34.9%   
Fx outflow Rs m1,7724,889 36.3%   
Net fx Rs m3,52510,312 34.2%   
CASH FLOW
From Operations Rs m1,274-115,975 -1.1%  
From Investments Rs m-1,204-8,265 14.6%  
From Financial Activity Rs m-196107,525 -0.2%  
Net Cashflow Rs m-126-16,650 0.8%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.0 7.5%  
FIIs % 9.6 26.6 36.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 16.5 55.2%  
Shareholders   42,599 93,274 45.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   WYETH LTD  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS